rs12044852 — CD58

CD58 rs12044852 — MS Risk and IFN-Beta Non-Response at the LFA-3 Locus

The CD58 gene¹¹ CD58 gene
CD58 encodes LFA-3 (Lymphocyte Function-Associated Antigen 3), a cell-surface glycoprotein that binds CD2 on T cells to stabilise the immune synapse and promote regulatory T cell expansion harbours a cluster of intronic variants in its first intron that collectively regulate LFA-3 expression and multiple sclerosis susceptibility. The rs12044852 C/A polymorphism is one of three strongly associated markers in this locus (alongside rs2300747 and rs1335532), linked by very high linkage disequilibrium (r²=0.929 between rs12044852 and rs2300747). What distinguishes rs12044852 from its LD partner is its documented pharmacogenomic relevance: the CC genotype not only elevates MS risk but also predicts poor response to interferon-beta, the most widely prescribed first-line MS therapy.

The Mechanism

Like its LD partner rs2300747, the rs12044852 C/A polymorphism sits within the first intron of CD58 and modulates LFA-3 (CD58) mRNA expression²² LFA-3 (CD58) mRNA expression
Higher LFA-3 expression strengthens CD2-mediated costimulatory signalling in regulatory T cells (Tregs), promoting FoxP3 expression and self-tolerance. The protective A allele is associated with higher CD58 mRNA levels, mirroring the effect seen at the companion rs2300747(G) allele. Carriers of the A allele therefore have a more robust CD2–LFA-3 interaction, driving stronger Treg induction and better immune self-regulation.

For IFN-beta response, the mechanism likely connects through CD58's role in modulating T-regulatory cell potency³³ T-regulatory cell potency
IFN-beta partly exerts its anti-inflammatory effect in MS by augmenting Treg numbers and function; impaired baseline Treg activity from CD58 deficiency may blunt this therapeutic leverage. Patients who start with a CD58-deficient immune set-point (CC genotype) may derive less clinical benefit from an immunomodulatory agent that depends on intact Treg circuitry. The shared intronic haplotype block also encodes hsa-miR-548ac⁴⁴ hsa-miR-548ac
A microRNA co-transcribed from the CD58 first intron; the risk haplotype raises miR-548ac and lowers CD58 mRNA from the same primary transcript via altered Drosha cleavage, whose elevated expression in risk carriers may further suppress immunoregulatory target genes relevant to IFN-beta signalling.

The Evidence

MS susceptibility: A case-control study by Omrani et al. 2015⁵⁵ Omrani et al. 2015
200 RRMS patients vs 200 healthy controls, Iranian population; genotyping by PCR-SSP; Hardy-Weinberg confirmed in both groups found the CC genotype in 83.5% of MS patients versus 69.5% of controls, yielding an OR of 2.22 (P=0.001). The A allele (minor allele, ~10% in Europeans) acts protectively: AA individuals were significantly less likely to have MS. This mirrors the pattern at the LD-partner rs2300747, where the G (minor) allele is protective, and is consistent with the shared haplotype interpretation that the same regulatory region drives both associations.

Independent replication by Booth et al. 2008 in 1,134 Australian MS cases and 1,265 controls⁶⁶ Booth et al. 2008 in 1,134 Australian MS cases and 1,265 controls confirmed CD58 rs12044852 as a susceptibility variant (P=0.042). The broader CD58 locus was confirmed at genome-wide significance (P=4×10⁻⁹) by Hoppenbrouwers et al. 2009⁷⁷ Hoppenbrouwers et al. 2009 and is among the 57 confirmed MS susceptibility loci in the large Sawcer et al. 2011 Nature GWAS⁸⁸ Sawcer et al. 2011 Nature GWAS
9,772 cases collected by 23 research groups across 15 countries.

IFN-beta response: Among 120 relapsing-remitting MS patients receiving IFN-beta therapy and followed over two years, Omrani et al.⁹⁹ Omrani et al. found striking genotype-stratified differences in Multiple Sclerosis Severity Score trajectory. The ΔMSSS (change from baseline) was 0.44 for CC carriers — the worst outcome group — compared with 0.03 for AC carriers (best responders) and 0.11 for AA carriers. The association between CC genotype and poor IFN-beta response was statistically significant (P<0.05). This is the first pharmacogenomic annotation of rs12044852 and represents the primary clinical utility distinguishing it from rs2300747.

Population genetics: the C allele is very common in Europeans (~90%) and Africans (~93%), but notably less so in East Asians (~42%), paralleling the lower MS burden in East Asian populations and matching the inverse pattern seen at rs2300747's protective G allele.

Practical Actions

For CC carriers — the large majority of European-descent individuals — the two key clinical implications are: (1) modest but real elevation of MS susceptibility requiring awareness of early warning signs and attention to modifiable risk factors, especially vitamin D; and (2) if MS develops and IFN-beta therapy is being considered, this genotype signals a higher likelihood of suboptimal therapeutic response. Discussing this with a neurologist before committing to IFN-beta over alternative disease-modifying therapies (natalizumab, ocrelizumab, dimethyl fumarate, or sphingosine-1-phosphate modulators) is worthwhile.

For AC or AA carriers, the protective A allele suggests better IFN-beta response and lower baseline MS susceptibility, though the A allele is rare (~10% in Europeans) and the AA genotype is uncommon (~1%).

Vitamin D optimisation is the strongest modifiable lever for all genotypes: sufficiency independently supports FoxP3 expression and Treg function through the vitamin D receptor pathway, partially compensating for reduced LFA-3-mediated Treg support.

Interactions

Within the CD58 locus, rs12044852 and rs2300747 are in near-complete LD (r²=0.929) and almost certainly tag the same functional haplotype. An individual's risk at one predicts their risk at the other. The companion variant rs1335532 is also in strong LD and appears to anchor the miR-548ac regulatory mechanism described by Hecker et al. 2019¹⁰¹⁰ Hecker et al. 2019.

The CD58 costimulatory axis intersects with rs6897932 (IL7R), which regulates T-cell homeostasis and Treg survival, and with PTPN22 rs2476601, which lowers the TCR activation threshold. Individuals carrying high-risk alleles across these loci face compounding impairments to immune self-tolerance. The pharmacogenomic IFN-beta response signal at rs12044852 adds a third dimension: genetic background may influence not just who develops MS but how well they respond to its first-line treatment.